Knight Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

DB:04K Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
21 Mar 25	Sell€10,149,073	G2s2 Capital Inc.	Company	2,500,000	€4.06
20 Mar 25	Sell€518,889	G2s2 Capital Inc.	Company	126,600	€4.11
19 Mar 25	Sell€5,187,698	G2s2 Capital Inc.	Company	1,305,000	€4.01
18 Mar 25	Sell€21,183	G2s2 Capital Inc.	Company	5,300	€4.00
17 Mar 25	Sell€363,460	G2s2 Capital Inc.	Company	92,200	€3.94
14 Mar 25	Sell€2,682,081	G2s2 Capital Inc.	Company	700,000	€3.83
13 Mar 25	Sell€431,993	G2s2 Capital Inc.	Company	111,600	€3.91
12 Mar 25	Sell€419,754	G2s2 Capital Inc.	Company	107,800	€3.92
04 Mar 25	Buy€63,131	G2s2 Capital Inc.	Company	17,600	€3.59
12 Nov 24	Buy€347,213	G2s2 Capital Inc.	Company	100,000	€3.49
11 Nov 24	Buy€69,475	Samira Sakhia	Individual	20,000	€3.47
16 Sep 24	Sell€1,215,481	G2s2 Capital Inc.	Company	300,000	€4.05
05 Jun 24	Buy€19,467	Jonathan Goodman	Individual	5,000	€3.89
29 May 24	Sell€99,784	Robert Lande	Individual	25,000	€4.00
23 May 24	Sell€80,055	Robert Lande	Individual	20,000	€4.00
09 May 24	Sell€299,020	G2s2 Capital Inc.	Company	74,100	€4.04

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of 04K?
Owner Type	Number of Shares	Ownership Percentage
Institutions	10,568,283	10.6%
Private Companies	14,931,013	15%
Individual Insiders	22,745,549	22.9%
General Public	51,295,239	51.5%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 48.26% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
21.9%	Jonathan Goodman	21,786,462	€84.8m	0.09%	no data
15%	Medici Strategic Portfolio Management Inc	14,931,013	€58.1m	15.1%	no data
2.87%	Industrielle Alliance, Gestion de placements inc.	2,859,009	€11.1m	0%	0.13%
2.61%	Dimensional Fund Advisors LP	2,597,538	€10.1m	1.11%	no data
1.9%	QV Investors Inc.	1,888,716	€7.4m	0%	0.41%
0.86%	COTE 100, Inc.	852,750	€3.3m	0%	2.51%
0.69%	Artisan Partners Limited Partnership	684,951	€2.7m	105%	no data
0.34%	Samira Sakhia	337,089	€1.3m	19.6%	no data
0.3%	McElvaine Investment Management Ltd.	300,000	€1.2m	200%	8.44%
0.26%	Bessemer Investment Management LLC	253,979	€988.6k	0%	no data
0.24%	Robert Lande	243,178	€946.6k	0%	no data
0.22%	Tredje AP-fonden	221,189	€861.0k	0%	no data
0.18%	CI Investment Consulting	175,829	€684.4k	0%	0.27%
0.17%	Amal Khouri	172,370	€671.0k	7.6%	no data
0.11%	Ampega Investment GmbH	112,000	€436.0k	12%	0.02%
0.11%	KLP Kapitalforvaltning AS	106,500	€414.5k	-11.4%	no data
0.08%	Brandes Investment Partners, LP	79,374	€309.0k	0%	no data
0.077%	SLGI Asset Management Inc.	77,130	€300.2k	0%	0.01%
0.069%	State Street Global Advisors, Inc.	68,797	€267.8k	-3.03%	no data
0.065%	Arvind Utchanah	64,485	€251.0k	48.8%	no data
0.058%	CI Global Asset Management	58,081	€226.1k	3.73%	no data
0.054%	BlackRock, Inc.	53,752	€209.2k	-4.2%	no data
0.053%	James Gale	52,406	€204.0k	0%	no data
0.036%	Northern Trust Global Investments	36,232	€141.0k	0%	no data
0.029%	Susan Emblem	28,826	€112.2k	29.1%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/07 02:03
End of Day Share Price	2025/05/07 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Knight Therapeutics Inc. is covered by 15 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
David Kideckel	Beacon Securities Limited
David Martin	Bloom Burton & Co.
Tania Armstrong-Whitworth	Canaccord Genuity